Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.42 |
| ▸ | ATF4 | P18848 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22373871 | 0.93 | HTT (0.41) | SCN9AATF4HTR7 | |
| Trifluoroacetic Acid SCHEMBL22777505 | 0.84 | CHRM1 (0.48) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL22362286 | 0.83 | SCN9A (0.50) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL21050177 | 0.81 | SMYD3 (0.50) | SCN9AATF4HTR7 | |
| Trifluoroacetic Acid SCHEMBL21050179 | 0.81 | SMYD3 (0.50) | SCN9AATF4HTR7 | |
| Trifluoroacetic Acid SCHEMBL22362300 | 0.80 | HDAC3 (0.45) | ATF4HDAC6 | |
| SCHEMBL22362262 | 0.80 | ATF4 (0.42) | SCN9AATF4HTR7 | |
| Trifluoroacetic Acid SCHEMBL22777267 | 0.78 | ATF4 (0.48) | SCN9AATF4HTR7 | |
| Trifluoroacetic Acid SCHEMBL22777264 | 0.78 | ATF4 (0.48) | SCN9AATF4HTR7 | |
| SCHEMBL28675852 | 0.78 | ATF4 (0.40) | SCN9AATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3930697-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-113840597-A | Integrated stress response pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20200270232-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270232-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | SCN9A 4611/4885ATF4 1/4885HDAC6 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.